Core Viewpoint - Heng Rui Medicine's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received a notice of acceptance from the National Medical Products Administration for its innovative drug SHR-1918 injection, which has been included in the priority review process [1] Group 1 - The drug SHR-1918 is intended for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH) [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for its innovative drug SHR-1918 injection, which has been included in the priority review process [1] Group 1: Product Development - SHR-1918 injection is a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), designed to lower serum triglycerides (TG) and LDL-C levels [1] - The total R&D investment for the SHR-1918 injection project has reached approximately 24.22 million yuan (unaudited) [1] Group 2: Market Context - The only other drug targeting the same pathway is Regeneron's EVKEEZA® (evinacumab-dgnb), which is projected to have global sales of about $216 million by 2025 according to EvaluatePharma [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for its innovative drug SHR-1918 injection, which is now included in the priority review process [1] Group 1 - SHR-1918 injection is designed for the treatment of adult and adolescent patients aged 12 and above with homozygous familial hypercholesterolemia (HoFH) [1] - The drug is a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), which works by inhibiting ANGPTL3 activity to lower serum triglycerides (TG) and LDL-C levels [1] - The total research and development investment for the related project has reached approximately 242 million yuan [1]

Core Insights - The article highlights the recent milestones in research and development for Heng Rui Medicine, particularly the inclusion of KRAS G12D inhibitor HRS-4642 for advanced pancreatic cancer treatment by the National Medical Products Administration [1] - The company is also advancing its clinical pipelines, including IL-17 monoclonal antibody SHR-1314 and GLP-1/GIP dual-target agonist HRS-9531, showcasing its R&D strengths [1] - A supply disruption incident involving partner Lingli Pharmaceutical is ongoing, with Heng Rui Medicine stating it is legally assisting in the matter without disclosing specific adjustments to the partnership [1] Stock Performance - As of February 13, the A-share price closed at 58.23 yuan, down 0.87%, with a trading volume of 2.009 billion yuan; the Hong Kong stock price as of February 20 was 69.25 HKD, down 2.33% [1] - Technical analysis indicates short-term volatility, with a resistance level at 60.76 yuan and a support level at 55.95 yuan [1] - On February 13, there was a net outflow of 130 million yuan from major funds, but institutional target prices average at 76.40 yuan, indicating a potential upside of 31.20% from the current price [1] Institutional Insights - As of February 18, it was noted that the revenue from innovative drugs for Heng Rui Medicine has reached 60.66%, indicating a shift in valuation logic towards pipeline-driven growth [1] - The company has the second-largest pipeline globally with 163 self-developed projects, yet its market capitalization stands at 67 billion USD, highlighting a disparity compared to similar international pharmaceutical companies [1] - Business development (BD) is expected to become a new growth driver, with projected external licensing revenue of 6 billion yuan in 2026, although there are concerns regarding the global competitiveness of the Fast Follow strategy [1]

Company Project Progress - The company announced that its subsidiary, Suzhou SNDY, received approval from the National Medical Products Administration (NMPA) for its innovative drug, Rilaforpu α injection, on January 8, 2026. This drug is indicated for first-line treatment in patients with PD-L1 positive locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma in combination with chemotherapy, marking a significant milestone in the company's innovative drug pipeline [1] - The company's innovative drug pipeline continues to expand, with multiple clinical trials at critical stages. As of the 2025 semi-annual report, there are 10 projects in Phase III and 22 projects in Phase II, indicating a need to monitor the application and approval progress of these pipelines in the future [2]

Core Viewpoint - Heng Rui Medicine (600276) emphasizes its commitment to technological innovation and international development strategies to ensure sustainable growth and better returns for shareholders [1] Group 1 - The company has received domestic approval for its self-developed innovative drug, Sulfate Emamectin Benzoate Tablets, aimed at treating adult patients with severe alopecia areata [1]

Core Viewpoint - Heng Rui Medicine (600276) confirmed that its daily operations and business conditions are normal, and there is no significant information that should have been disclosed but was not [1] Group 1 - The company is actively engaging with investors through an interactive platform [1] - The company reassured investors about its operational stability [1] - There are no undisclosed major issues affecting the company's performance [1]

Core Viewpoint - The keyword for the stock market in 2025 is expected to be "innovative drugs," with significant stock price increases driven by the potential of in-development innovative drugs and BD (business development) transactions rather than traditional revenue from already marketed drugs [1] Group 1: BD Transactions - In 2025, China's innovative drug BD transaction total exceeded $100 billion, with notable orders reaching $10 billion, and upfront payments from multinational pharmaceutical companies reaching a new high of $1.25 billion [1] - Landmark transactions include a $13 billion collaboration between Qihuang Dejian and Biohaven/AimedBio in January, marking a milestone for China's ADC technology [2] - In May, 3SBio's deal with Pfizer exceeded $6 billion, setting a record for upfront payments in China at $1.25 billion, highlighting the value of both first-in-class and fast-follow drugs [2] - In July, a $12 billion strategic partnership between Hengrui Medicine and GlaxoSmithKline showcased the depth of early-stage pipelines in leading Chinese pharmaceutical companies [2] - In October, Innovent Biologics and Takeda's collaboration worth $11.4 billion included a cost-sharing model for global R&D, enhancing operational capabilities for future international ventures [2] Group 2: Milestone Payments and Emerging Fields - Several past BD transactions reached milestone payments in 2025, including a $300 million payment to China National Pharmaceutical's subsidiary from Merck and a $250 million payment to Bairui Tianheng from Bristol-Myers Squibb [3] - The focus of BD transactions is shifting from oncology to other therapeutic areas, with autoimmune diseases, metabolism, and central nervous system disorders emerging as new hot fields [3] - Notable deals include the global rights licensing of BTK inhibitor Orelabrutinib for multiple sclerosis by Nocera Biopharma, with a potential total transaction value exceeding $2 billion [3] - The metabolic field is gaining traction, driven by global weight loss trends, with several companies entering into licensing agreements for GLP-1 targeted drugs [3] Group 3: Independent Clinical Trials and Regulatory Approvals - Numerous innovative drug companies in China are advancing their own overseas clinical trials, achieving significant progress [4] - In early 2025, Dize Pharmaceutical's lung cancer targeted drug received priority review from the FDA and was approved in July, becoming the first globally innovative drug independently developed in China to gain approval in the U.S. [4] - Other advancements include breakthrough therapy designations for CS0159 by Kexi Kedi and a Phase III trial approval for a recombinant human albumin injection by Heyuan Biopharma [4] - These developments indicate that the Chinese innovative drug industry is becoming a significant force in global innovation, transitioning from fast-following to original innovation and integrating deeply into the global value chain [4]

Core Viewpoint - Recently, HRS-5346, developed by the subsidiary of Heng Rui Medicine, Shandong Shengdi Pharmaceutical Co., Ltd., has been included in the list of breakthrough therapeutic drugs by the National Medical Products Administration (NMPA) for the treatment of elevated lipoprotein(a) levels [1][7]. Group 1: Company Information - HRS-5346 is an oral small molecule Lp(a) inhibitor that works by blocking the initial non-covalent binding between apolipoprotein(a) [apo(a)] and apolipoprotein B100 (ApoB100), thereby inhibiting the formation of disulfide bonds and reducing Lp(a) levels [3][9]. - The company plans to grant global exclusive rights for HRS-5346 outside of Greater China to Merck & Co., Inc. in March 2025 [4][9]. Group 2: Industry Context - Elevated lipoprotein(a) [Lp(a)] levels are the most common single-gene lipid disorder globally, with prevalence rates among Chinese adults exceeding 30 mg/dL and 50 mg/dL at 18.67% and 8.41%, respectively [2][9]. - Lp(a) elevation has been confirmed as an independent risk factor for atherosclerotic cardiovascular diseases (ASCVD), including coronary heart disease, ischemic stroke, peripheral vascular disease, and calcific aortic valve stenosis [2][9]. - Targeting Lp(a) with lipid-lowering therapies represents a potential new direction in the prevention and treatment of cardiovascular diseases, although no specific treatment for lowering Lp(a) is currently available, and such therapies remain in clinical research [2][9].

Core Viewpoint - The news highlights the submission of SHR-1918, a new lipid-lowering drug developed by Shengdi Pharmaceutical, a subsidiary of Heng Rui Medicine, for the treatment of homozygous familial hypercholesterolemia (HoFH) in adults and adolescents aged 12 and above [1][2]. Group 1: Drug Development and Approval - SHR-1918 is an ANGPTL3 monoclonal antibody that lowers triglyceride (TG) levels and low-density lipoprotein cholesterol (LDL-C) levels by inhibiting the activity of ANGPTL3, which plays a crucial role in lipid metabolism [2][7]. - The drug received breakthrough therapy designation for HoFH from the CDE in September 2024 and was included in priority review last month [2][7]. - A Phase III registration study for SHR-1918 began in December 2024 and was marked as "completed" in November 2025, with results yet to be disclosed [5][10]. Group 2: Clinical Trial Results - A single-arm, non-randomized Phase II clinical study showed that after 12 weeks of treatment with SHR-1918 (600mg, subcutaneously every 4 weeks), LDL-C levels decreased by 59.09% [3][8]. - In a randomized controlled Phase II clinical study, after 16 weeks of treatment, LDL-C levels were reduced by 21.7%, 27.3%, 29.9%, and 22.5% for the 150mg, 300mg, 600mg (every 4 weeks), and 600mg (every 8 weeks) dosage groups, respectively [3][8]. Group 3: Market Context and Competition - HoFH is a rare and severe genetic disorder characterized by a defect or absence of low-density lipoprotein cholesterol receptors (LDLR), leading to increased LDL-C levels in the blood and heightened risk of heart disease and stroke [6][12]. - Current treatment options for HoFH include statins, ezetimibe, lomitapide, mipomersen, PCSK9 monoclonal antibodies, and evinacumab, with evinacumab being the only marketed ANGPTL3 monoclonal antibody, projected to generate $162 million in U.S. sales by 2025 [6][12].